TE

Telix Pharmaceuticals Ltd

Develops radiopharmaceuticals that use targeted radiation to image and treat various cancers.

TLX | US

Overview

Corporate Details

ISIN(s):
AU000000TLX2
LEI:
Country:
United States of America
Address:
55 FLEMINGTON ROAD, 3051 NORTH MELBOURNE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Telix Pharmaceuticals Ltd. is a commercial-stage biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic ('theranostic') radiopharmaceuticals. The company's core approach involves using targeted radiation to both image and treat various forms of cancer. Its extensive pipeline addresses urologic oncology (prostate and kidney), neuro-oncology (glioma), and musculoskeletal oncology (sarcoma). Telix has achieved global regulatory approvals, including from the U.S. FDA, for its prostate cancer imaging agent and supports its portfolio with a robust global supply, manufacturing, and distribution network.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Telix Pharmaceuticals Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Telix Pharmaceuticals Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Telix Pharmaceuticals Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Greenwich LifeSciences, Inc. Logo
Developing an immunotherapy vaccine to prevent recurrence in HER2-positive breast cancer patients.
United States of America
GLSI
GRI Bio, Inc. Logo
Advancing NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases.
United States of America
GRI
Grifols S.A. Logo
Leading producer of plasma-derived medicines for patients with rare and chronic diseases.
Spain
GRF
Grindeks Logo
Develops & manufactures pharmaceuticals for cardiovascular, CNS, cancer, and diabetes globally.
Latvia
GRD1R
GT Biopharma, Inc. Logo
Develops TriKE® immunotherapies engaging NK cells to treat hematologic and solid tumor cancers.
United States of America
GTBP
Guardant Health, Inc. Logo
Develops liquid biopsies for cancer detection, monitoring, and personalized treatment guidance.
United States of America
GH
Guard Therapeutics International AB Logo
Clinical-stage biotech developing drugs to prevent acute kidney injury during open-heart surgery.
Sweden
GUARD
Develops research antibodies and distributes scientific instruments for life science researchers.
South Korea
036180
GYRE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing novel drugs for liver fibrosis and pneumoconiosis.
United States of America
GYRE
Haleon PLC Logo
A global consumer healthcare leader providing trusted, science-backed OTC brands for everyday health.
United Kingdom
HLN

Talk to a Data Expert

Have a question? We'll get back to you promptly.